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A b s t r a c t
Background: It is difficult to define the optimal management of elderly heart failure (HF) patients with complex comorbidi-
ties. Thus, comprehensive characterisation of HF patients constitutes a crucial pre-condition for the successful management
of this fragile population.
Aim: To analyse the ‘real life’ HF patients, including the evaluation of their health conditions, management and their use of
public health resources.
Methods and results: We examined 822 consecutive patients diagnosed with HF in NYHA classes II–IV in primary care
practices. The mean age was 68.5 years, and 56% were male. Only 23% of the patients who were of pre-retirement age
remained professionally active. Ischaemic or hypertension aetiology was found in 90% of participants. Nearly all patients had
multiple comorbidities. Most patients received converting enzyme inhibitors (88%) and beta-blockers (77%), 60% of them
both, although dosing was frequently inadequate. During the six months preceding the study, 31% had cardiovascular hospi-
talisation and 66% required unscheduled surgery visits.
Conclusions: The real life HF population differs from trial populations. Most of the real life patients who had not yet reached
retirement age were professionally inactive, mainly due to a disability caused by cardiovascular conditions. Moreover, ex-
tremely few participants were free from any comorbidity. Compared to 20th century Polish data, there has been an improve-
ment in the overall quality of HF-recommended pharmacotherapy. It must be stressed, however, that the percentage of
those on optimal dosage remains unsatisfactory.
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INTRODUCTION
Heart failure (HF) remains one of the leading, most costly,
disabling and deadly conditions encountered by a most phy-
sicians. The HF prevalence in the general population in deve-
loped countries is estimated at 0.4% to 2% [1]. Thus, it can
be assumed that 600,000 to 700,000 patients in Poland may
be affected. The ageing of the general population and advan-
ces in the treatment of cardiovascular disease (CVD) have led
to a gradual growth in the HF population, increasing the per-
centage of patients requiring hospitalisation and intensive
medical care. The HF is assumed to be responsible for about
5% of all medical and geriatric admissions and is the number
one cause of hospitalisation in people aged 65 and over, con-
suming approximately 1–2% of the entire health care budget
in developed countries.
Over the last two decades, we have gathered evidence
from clinical trials showing the effectiveness of proper phar-
macotherapy in reducing HF morbidity and mortality [2]. Even
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so, it is not easy to define the best management of elderly HF
patients with complex comorbidities presenting in everyday
practice, who differ substantially from trial populations [3].
Thus, understanding real HF patients constitutes a crucial pre-
condition for the successful management of this fragile popu-
lation.
The aim of this study was to analyse the real world of HF
patients drawn from primary care physicians’ (PCPs) practices,
with evaluation of their health conditions, medical manage-
ment and the impact they have on health system resources.
METHODS
Our data represents baseline characteristics of participants in
the ZOPAN study (RandomiZed InterventiOnal Ambulatory
Programme in Heart FAilure PatieNts), a multicentre national
project (conducted as part of a national programme into the
prevention and treatment of CVD known as POLKARD) co-
ordinated by the Institute of Cardiology in Warsaw. There
were a total of nine co-ordinating centres located in medium-
-sized and large cities in several regions of Poland, run by
cardiology specialists and their assistants who were chosen
by the project’s main co-ordinators, in a similar manner to
the EuroHeart Failure Survey (EHFS) [4]. Regional co-ordina-
tors were responsible for recruiting clusters of PCPs (who had
all volunteered to participate in this project) and supervised
the recruitment of HF patients by participating PCPs over the
course of six months in 2004–2005. The investigation con-
formed to the principles outlined in the Declaration of Hel-
sinki. The study protocol was accepted by the Local Ethics
Committees and all participants gave their informed consent.
Population
The PCPs engaged in this project were asked to register con-
secutive patients who had been diagnosed with HF, were over
the age of 18, had sought medical care in outpatient settings
(regardless of cause), and had symptoms corresponding to
NYHA classes II–IV.
Eligibility for this study required meeting several criteria.
Patients had to have clinical symptoms of HF (as described in
European Society of Cardiology (ESC) HF guidelines) [2]: bre-
athlessness, tiredness/fatigue and peripheral oedema), accom-
panied by either: (1) confirmed systolic dysfunction by echo-
cardiography defined by ejection fraction (EF) < 45% (within
the last 24 months) or (2) both abnormal resting ECG and
chest X-ray (performed within the last 12 months). Abnormal
ECG was defined as past myocardial infarction (MI), conduc-
tion abnormalities, left ventriclular hypertrophy (LVH), or ar-
rhythmias; chest X-ray was considered abnormal when car-
dio-thoracic ratio was > 50% or heart silhouette was enlar-
ged with at least moderate pulmonary congestion.
All subjects were evaluated via a questionnaire (collec-
ted by PCPs), which included patients’ medical history, NYHA
class, laboratory tests (ECG, chest X-ray, echocardiogram,
when available), etiology of HF, pharmacotherapy and utili-
sation of health system resources within the six months pre-
ceding the study (surgery visits and/or hospitalisation). Cau-
ses of hospitalisation were classified by PCPs, based on the
discharge summaries.
The assessment of optimal dosing of angiotensin conver-
ting enzyme inhibitor (ACEI) and beta-blocker (BB) antagoni-
sts was based on the recommendation of the ESC [2]. The
same guidelines were used for classification of BB prepara-
tion accepted in HF (metoprolol, bisoprolol, carvedilol, nebi-
volol). Before starting the project, all PCPs underwent training
in HF management, to assure a consistent level of care.
Statistical analysis
Figures from all participating centres were pooled and analy-
sed in the central statistics centre (Office of Biostatistics in the
Department of Epidemiology and CVD Prevention of the In-
stitute of Cardiology). All statistical analyses were performed
using SAS software (SAS Institute, Cary, NC, USA). Depen-
ding on the parameter analysed, they were presented either
as a percentage or as a means ± SD.
RESULTS
The total population comprised 822 subjects recruited by
PCPs. For 55% of the subjects, echocardiography inclusion
criteria were applied, whereas the remaining 45% were re-
cruited using ECG and chest X-ray criteria.
Demographic and sociological data
The distribution of males and females was comparable, with
slightly more men. Mean age in the study group was 68.5 ye-
ars (range 33–97 years). Average body mass index (BMI) was
above normal, corresponding to the ‘overweight’ category.
One in ten patients was an active smoker. More than half of
the subjects had finished their education at primary or voca-
tional level. A minority of the study population consisted of
subjects living alone (single, widowed or divorced). In the
subjects of pre-retirement age, a small percentage remained
professionally active. Of those who were no longer working,
more than three quarters were in receipt of a disability pen-
sion, mostly due to CVDs (Table 1).
Clinical history
The mean time elapsed since HF diagnosis was 4.5 years.
Our population consisted mainly of subjects in the early sta-
ges of HF (NYHA II), with only one third of the population in
a more advanced stage. The predominant aetiology was ischa-
emic or hypertensive or both. The remainder (nearly 10%)
included cases of dilated cardiomyopathy, alcoholic cardio-
myopathy and valvular heart disease (Table 2).
Clinical history revealed that only 2.7% of subjects had
no comorbidities, and the highest number of coexisting dise-
ases was seven (Table 3). Of all CVDs, coronary artery dise-
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ase and hypertension were the most commonly found, whe-
reas diabetes and pulmonary diseases were the most com-
monly-found non-CV conditions. Other comorbidities, infre-
quently documented by their medical history (ranging from
1–3%) included liver insufficiency, prostate disease, gastroin-
testinal ulcerous disease, venous disease, anaemia, and Par-
kinson’s disease.
Management: diagnostic procedures and treatment
Echocardiography was performed in 79% of patients, and the
mean EF was 39% (in tests from the last 12 months). Chest X-
-ray was carried out on almost all participants (97%) and was
described as abnormal in 89%, whereas ECG was done in
99% and was abnormal in 96%. Based on the description of
ECG provided by PCPs, the following abnormalities were fo-
und: atrial fibrillation (32%), other forms of arrhythmias (19%),
conduction abnormalities (21%), ischaemic changes (19%),
past MI (36%) and LVH (41%). During the six months prece-
ding the study, potassium and creatinine levels were chec-
ked at least once in approximately three quarters of subjects,
and in 10% were abnormal.
Treatment pattern evaluation showed that nearly 90% of
subjects were on ACEI. However the recommended doses were
prescribed in half of them (Table 4). The main reasons for not
administering ACEI included intolerance, hypotension, renal
dysfunction and hyperkalemia, whereas lower than usual do-
sage resulted from hypotension, side effects (renal dysfunction
and a tendency towards hyperkalemia) (Fig. 1). Angiotensin
receptor blockers, were used in a negligible proportion of pa-
tients. The percentage of patients on BB was high (77%) but
recommended BBs were administered in 67%. Similarly to
ACEI, BB doses were much lower than those recommended
and only a minority of patients received the optimal dosage
(Table 4). The main reasons given for avoiding BB were low
Table 1. Characteristics of the study population
Age [years] 68.5 ± 10.7
Male gender 56%
Body mass index [kg/m2] 28.9 ± 5.2
Smoking 10%




Disability pension (disability due to CVD)*** 83% (87%)
*Unmarried status includes: single, divorced, widowed; **% of those of
pre-retirement age (women < 60 years, men < 65 years); ***% of those
not professionally active of pre-retirement age (women < 60 years,
men < 65 years) on disability pension; CVD — cardiovascular diseases




Ischaemic + hypertension 38%

















Coronary artery disease (MI in the past) 77% (52%)
Hypertension 73%








*Total does not equal 100% due to approximation; **defined as
transient ischaemic attack or stroke; MI — myocardial infarction;
COPD — chronic obstructive pulmonary disease
Table 4. Heart failure pharmacotherapy
ACEI/optimal dosage of ACEI 88%/52%
BB/optimal dosage of BB 77% (67%)*/22%
Combination of ACEI and BB (accepted in HF)* 60%




*Data in brackets for beta-adrenolytic agents accepted in heart failure
(HF) — see methodology; ACEI — angiotensin converting enzyme
inhibitors; BB — beta-blockers
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blood pressure, bradycardia, pulmonary diseases and symp-
toms of intolerance, whereas lower dosage was mainly due to
progression of HF or pulmonary symptoms and a tendency
towards bradycardia or hypotension (Fig. 2). A combination
therapy, with both ACEI and BB, was used in about 60% of
study participants. Almost half of the population received al-
dosterone antagonists. Diuretics were among medications re-
commended most often in this population, with loop diuretics
leading the group. Conversely, digoxin, was used by only one
quarter of the population studied (Table 4). The HF medica-
tions constituted only a subset of the drugs used. Other most
frequently administered CV drugs included aspirin (64%), sta-
tins (55%), long-acting nitrates (40%), calcium channel bloc-
kers (40%), acenocoumarol (23%), amiodarone (5%) and other
antiarrhythmic medications (2%).
Utilisation of health service resources
Assessing the frequency of office visits and hospitalisations in
the six months preceding the study revealed that nearly one
in three subjects were hospitalised due to CV causes. More-
over, two thirds of participants claimed that they required
unscheduled office visits because of HF symptoms deteriora-
tion during the time analysed (Table 5).
DISCUSSION
This study looked at ambulatory HF patients recruited from
PCPs’ practices. As the recruitment centres covered most re-
gions of Poland, we can assume that the studied population
mirrors the real population of ambulatory HF patients. More-
over, our data show a broader picture, as most published
epidemiological projects have been limited to a single cen-
tre/region [1, 5, 6] and have mainly involved hospitalised po-
pulations [4, 7, 8]. In published studies based on subjects
from general practices/population, ESC requirements of ob-
jective visualisation for HF diagnosis have not always been
followed [5]. In most of them, the diagnosis of HF was based
on clinical criteria and physicians’ experience, as in the EHFS
[7]. Some used both objective and clinical criteria [9].
The age distribution of the study population was similar
to previous findings of the age distribution of the Polish po-
pulation [4, 10–13]. Likewise, observed equal gender distri-
bution is in line with most of previous papers, constituting
an obvious difference from the populations enrolled in cli-
nical trials [6, 12–14]. Also, the trends for obesity are consi-
stent with data regarding the Polish population, although
smoking prevalence was lower [8].
Unsurprisingly, we observed that less than one quarter
of the subjects of pre-retirement age remained professionally
active. Disability pension (in 90% of cases due to CVDs) was
the main cause of professional inactivity. This finding of a ge-
nerally high impact of the disease on the patients’ work status
probably contributes to the generally low quality of life with
this condition. Moreover, it adds to the financial consequen-
ces of the disease.
The prevalence of ischaemic heart disease, alone or in
combination with hypertension, as the commonest aetiology
of HF, is in line with previous reports regarding the Polish
population [8, 11]. In general, the high prevalence of corona-
ry aetiology is a common finding in HF patients from clinical
practice, in contrast to observations made in clinical trials [2].
The fact that more than half of our population had at
least three coexisting diseases confirms previous findings [3].
Figure 1. Reasons for not receiving angiotensin converting enzyme inhibitor (A) or for its suboptimal dosing (B)
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On the other hand, a Dutch study showed a much lower
proportion (25%) of multiple comorbidities [6].
With regard to CV conditions, our results are compara-
ble with EHFS results, showing similar proportions for ischa-
emic heart disease and MI [15]. Hypertension was more pre-
valent, but comparable to recent observations made of the
Polish population [8, 13].
In the HF population, non-CV conditions are a signifi-
cant challenge, as they influence treatment options and add
to the burden of polytherapy. In fact, Braunstein et al. [3]
documented that some patients had as many as ten non-CV
comorbidities. Diabetes and pulmonary disease are among
the most frequently reported (usually 20–30%) [3, 6, 10, 15],
with renal failure reaching at most 20% [16]. The difference
with regard to frequency of renal failure might be due to im-
precise descriptive criteria of renal dysfunction in our study.
Populations with more comorbidities are at a greater risk of
adverse events and preventable hospitalisation, producing
higher costs for health systems.
Atrial fibrillation is one of the arrhythmias reported most
often in HF, reaching as much as 40–50% [13, 16, 17]. Ne-
vertheless, in EHFS and IMPROVEMENT it was overall sligh-
tly above 20% [4, 10]. So, our results, showing a prevalence
of 32%, lie in the middle. Other findings from ECG are not
often reported in publications, despite the fact that previous
infarction, LVH and bundle branch block are well known risk
factors for an adverse prognosis [2].
Availability of echocardiography remains a weak point
in the management of the HF population, despite an impro-
vement in comparison to previous studies [11]. Based on the
recent data, echocardiography was not performed in more
than 50% of patients cared for by non-cardiologists (both out-
and in-patients). Results were better for specialist care (both
out- and in-patients, 24% and 18–27%, respectively) [8, 13].
Considering these reports, our finding confirms a substantial
improvement, although the situation remains unsatisfactory.
At present, a combination of ACEI and BB is regarded
as a cornerstone of treating HF with reduced systolic func-
tion [2]. Our data, showing 88% of subjects on ACEI and
77% on BB, is an impressive improvement compared with
the studies conducted at the turn of this century, where ACEI
was used in 60–62%, and BB in 34–37% [10, 14]. In subse-
quent reports from the Polish population, ACEIs were ad-
ministered in 80–95% [7, 13], consistent with our current
findings. Only a few other reports [17] have been similar,
whereas in others the numbers remained lower [9, 15]. Only
Table 5. Hospitalisation and unscheduled office visits within the
six months preceding the study
CV hospitalisation 31%
Number of CV hospitalisations per patient 1.3 ± 0.6
Number of HF hospitalisations per patient 1.2 ± 0.6
Unscheduled office visits caused by HF 61%
Number of unscheduled office visits caused 2.8 ± 2.3
by HF per patient
Continuous data presented as means ± SD; CV — cardiovascular; HF —
heart failure; CV hospitalisation defined as hospitalisation due to CV
reasons; HF hospitalisations defined as hospitalisation due to HF reasons
Figure 2. Reasons for not receiving beta-blocker (A) or for its suboptimal dosing (B)
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a limited number of studies have analysed not only prescrip-
tion patterns, but also optimal dosage. The current data,
implicating target dosing in 50% for ACEI and 22% for BB,
must be considered a remarkable improvement in relation
to previous Polish data [8, 14, 17]. Similarly to previous re-
ports [8, 14], our population received a broader range of BB
preparations than recommended by ESC [2]. The commo-
nest reasons for not prescribing ACEI or BB (intolerance, renal
failure and hyperpotasemia, low blood pressure, pulmona-
ry disease) were similar to a previous report regarding a ho-
spital population [8]. Aldosterone antagonists, conversely to
ACEI and BB, are recommended in patients in advanced
HF. Nevertheless, in our study only 29% of participants were
in NYHA classes III and IV, suggesting their overuse. Identi-
cal findings in this regard were presented in two previous
studies of a Polish population [8, 14], although they have
been contradicted by other authors [10, 14, 17]. These fin-
dings suggest that there may be insufficient concern about
the safety of these agents, something which has been bro-
ught up recently by Jensen et al. [17] who showed that al-
dosterone antagonists in elderly HF patients modifies pro-
gnosis unfavourably. As recent clinical trials did not confirm
the advantage of statins in HF [2], their use along with aspi-
rin is justified by a history of ischaemic heart disease, and in
fact indicates a higher level of secondary prevention than
previously reported [8, 10, 14].
Most papers, based on patients with index HF hospitali-
sation, have analysed the number of readmissions, showing
the risk for subsequent all-cause hospitalisation within 30 days
to be 13.8% [18], and for 6–12 months ranging from 40%
[18] up to 65%. Therefore, the highest risk is likely to be ob-
served within a short time after the initial event. In this study,
we saw CV hospitalisation in 31% of subjects within six mon-
ths. In addition to hospitalisations, which are the main pro-
blems in regular care of HF patients, as many as 61% of them
reported attending unscheduled surgery visits due to HF-re-
lated problems (an average of one visit every second month),
a high usage of health services resources.
Importance of the study
One of the major benefits of the presented data is the signifi-
cant number of subjects included from several centres and
different regions of Poland. It should be stressed that our stu-
dy looks at HF patients at population level, cared for by PCPs,
not cardiology specialists. Thus, our results provide informa-
tion about the management of ambulatory HF patients in
everyday practice, who differ significantly from participants
in clinical trials (who tend to be mostly young men free of
any serious comorbidities).
Limitations of the study
This study has some limitations which must be addressed.
1. Participating PCPs were not chosen randomly. This mi-
ght influence the data, and we cannot guarantee that this
HF group is 100% representative of the adult HF popula-
tion in Poland. However, there was some random selec-
tion of participants, because we included subsequent
patients with HF showing up at PCPs’ settings.
2. Although we assume that all consecutive patients with
HF diagnosis had been registered, we were not able to
verify if the participating PCPs fully complied with this
requirement.
3. We were unable to verify the diagnosis of HF, or to di-
stinguish between systolic and diastolic HF objectively in
all subjects, as the echocardiography testing was limited.
However, in those in whom echocardiography was per-
formed, the EF was low, which reassures us that the dia-
gnoses were correct.
CONCLUSIONS
The real life HF population differs from trial populations. Most
of the real life patients who had not yet reached retirement
age were professionally inactive, mainly due to a disability
caused by cardiovascular conditions. Moreover, extremely few
participants were free from any comorbidity. Compared to
20th century Polish data, there has been an improvement in
the overall quality of HF-recommended pharmacotherapy. It
must be stressed, however, that the percentage of those on
optimal dosage remains unsatisfactory.
Acknowledgements
The authors would like to thank all of the participating physi-
cians whose contribution made this possible. This study was
supported by a scientific grant from the Ministry of Health —
POLKARD programme contract no: 7/115/2003/101/1304.
ClinicalTrials.gov ID: NCT00953810.
References
1. Ho KK, Anderson KM, Kannel WB et al. Survival after the onset
of congestive heart failure in Framingham Heart Study Sub-
jects. Circulation, 1993; 88: 107–115.
2. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC guidelines
for the diagnosis and treatment of acute and chronic heart fail-
ure. Eur J Heart Fail, 2008; 10: 933–989.
3. Braunstein JB, Anderson GF, Gerstenblith G et al. Noncardiac
comorbidity increases preventable hospitalizations and mor-
tality among medicare beneficiaries with chronic heart fail-
ure. J Am Coll Cardiol, 2003; 42: 1226–1233.
4. Cleland JGF, Swedberg K, Follath F et al. The EuroHeart Fail-
ure survey programme: a survey on the quality of care among
patients with heart failure in Europe Part 1: patient character-
istics and diagnosis. Eur Heart J, 2003; 24: 442–463.
5. Bleumink GS, Knetsch AM, Sturkenbooma MCJM et al. Quan-
tifying the heart failure epidemic: prevalence, incidence rate,
lifetime risk and prognosis of heart failure The Rotterdam Study.
Eur Heart J, 2004; 25: 1614–1619.
6. van Jaarsveld CHM, Ranchor AV, Kempen GIJM et al. Epide-
miology of heart failure in a community-based study of sub-
jects aged ≥ 57 years: Incidence and long-term survival. Eur
J Heart Fail, 2006; 8: 23–30.
7. Wierzchowiecki M, Poprawski K, Nowicka A et al. A new
programme of multidisciplinary care for patients with heart
30
www.kardiologiapolska.pl
Tomasz M. Rywik et al.
failure in Poznań: one-year follow-up. Kardiol Pol, 2006; 64:
1063–1070.
8. Rywik TM, Zieliński T, Piotrowski W et al. Heart failure pa-
tients from hospital settings in Poland: Population characteris-
tics and treatment patterns, a multicenter retrospective study.
Cardiol J, 2008; 15: 169–180.
9. Parashar S, Katz R, Smith NL et al. Race, gender, and mortality in
adults >65 years of age with incident heart failure (from the Car-
diovascular Health Study). Am J Cardiol, 2009; 103: 1120–1127.
10. Cleland JGF, Cohen-Solal A, Aguilar JC et al. Management of
heart failure in primary care (the IMPROVEMENT of Heart Fail-
ure Programme): an international survey. Lancet, 2002; 360:
1631–1639.
11. Rywik SL, Wagrowska H, Broda G et al. Heart failure in pa-
tients seeking medical help at outpatients clinics. Part I. Ge-
neral characteristics. Eur J Heart Fail, 2000; 2: 413–421.
12. Rywik TM, Rywik SL, Korewicki J et al. A survey of outpa-
tients management of elderly heart failure patients in Poland:
treatment patterns. Int J Cardiol, 2004; 95: 177–184.
13. Fedyk-Łukasik M, Zdrojewski T, Wizner et al. Heart failure
management in Poland: the National Cardiovascular Disease
Prevention and Treatment Program POLKARD, edition 2003–
–2005. Cardiol J, 2007; 14: 552–560.
14. Komajda M, Follath F, Swedberg K et al. The EuroHeart Fail-
ure Survey programme: a survey on the quality of care among
patients with heart failure in Europe. Part 2: treatment. Eur
Heart J, 2003; 24: 464–474.
15. Lainšcak M, Cleland JGF, Lenzen MJ et al. International varia-
tions in the treatment and co-morbidity of left ventricular sys-
tolic dysfunction: Data from the EuroHeart Failure Survey. Eur
J Heart Fail, 2007; 9: 292–299.
16. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S et al. Char-
acteristics and Outcomes of Patients With Heart Failure in
General Practices and Hospitals Japanese Cardiac Registry
of Heart Failure in General Practice. Circ J, 2007; 71: 449–
–454.
17. Jensen J, Hedin L, Widell C et al. Characteristics of heart fail-
ure in the elderly — a hospital cohort registry-based study. Int
J Cardiol, 2008; 125: 191–196.
18. Kosiborod M, Lichtman JH, Heidenreich PA et al. National
trends in outcomes among elderly patients with heart failure.




dr n. med. Tomasz M. Rywik, Klinika Niewydolności Serca i Transplantologii, Instytut Kardiologii, ul. Alpejska 42, 04–628 Warszawa,
tel: +48 22 343 43 48; faks: +48 22 343 45 22, e-mail: rywikt@mp.pl
Praca wpłynęła: 10.06.2010 r. Zaakceptowana do druku: 20.10.2010 r.
Charakterystyka populacji chorych
z niewydolnością serca w Polsce:
ZOPAN — badanie wieloośrodkowe
Tomasz M. Rywik1, Piotr Kołodziej2, Ryszard Targoński3, Małgorzata Fedyk−Łukasik4, Anna Nowicka5,
Elżbieta Zinka6, Bogdan Zbyszyński7, Piotr Achremczyk8, Jacek Górski9, Andrzej Muder2, Jerzy Sadowski3,
Przemysław Leszek1, Paweł Kurjata1, Grażyna Broda1, Jerzy Korewicki1
1Instytut Kardiologii, Warszawa; 2Wojewódzki Szpital Specjalistyczny, Siedlce; 3Miejski Szpital Zespolony, Olsztyn; 4Uniwersytet Jagielloński,
Kraków; 5Uniwersytet Medyczny, Poznań; 6Szpital Wojewódzki, Koszalin; 7Specjalistyczny Szpital Wojewódzki, Ciechanów; 8Szpital Miejski,
Radom; 9Gdański Uniwersytet Medyczny, Gdańsk
S t r e s z c z e n i e
Wstęp: Ustalenie optymalnego leczenia pacjentów w podeszłym wieku z niewydolnością serca (HF), którzy są obciążeni
wieloma chorobami współistniejącymi, jest zagadnieniem szczególnie trudnym. Dlatego też podstawą skutecznego postępo-
wania w tej grupie osób jest dokładna charakterystyka populacji.
Cel: Celem pracy była analiza charakterystyki chorych z HF na podstawie codziennej praktyki lekarskiej, z oceną ich stanu
zdrowia, jakości opieki oraz stopnia obciążenia dla systemu opieki zdrowotnej.
Metody i wyniki: Do badania włączono 822 kolejnych pacjentów ambulatoryjnych z HF w II–IV klasie NYHA z ośrodków
podstawowej opieki zdrowotnej. Średni wiek badanej grupy wynosił 68,5 roku, 56% stanowili mężczyźni, a 23% pacjentów
w okresie przedemerytalnym pozostawała aktywna zawodowo. Etiologia niedokrwienna lub nadciśnienie tętnicze było wska-
zywane jako przyczyna HF w 90% przypadków. Choroby współistniejące stwierdzano u prawie wszystkich badanych osób.
Większość pacjentów otrzymywała inhibitory enzymu konwertującego angiotensynę (88%), a 77% — beta-adrenolityki,
z czego 60% chorych przyjmowało połączenie tych dwóch leków, przy czym ich dawkowanie było niższe od zalecanego.
W okresie 6 miesięcy poprzedzających badanie 31% osób było hospitalizowanych z przyczyn sercowo-naczyniowych, a 66%
wymagało dodatkowych, nieplanowanych wizyt lekarskich.
Wnioski: Rzeczywisty obraz populacji chorych z HF różni się od opisywanego w badaniach klinicznych. Większość pacjen-
tów w okresie przedemerytalnym była nieaktywna zawodowo, przede wszystkim z powodu chorób sercowo-naczyniowych.
Dodatkowo brak chorób współistniejących stwierdzano jedynie u niewielkiego odsetka osób. W porównaniu z poprzednimi
danymi w przypadku populacji polskiej poprawiła się jakość opieki nad chorymi z HF w odniesieniu do stosowanej farmako-
terapii, nadal jednak dawkowanie leków odbiega od standardów.
Słowa kluczowe: niewydolność serca, postępowanie, populacja ogólna
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